Confidential Severance Agreement And general Release
Exhibit 10.1
Confidential Severance Agreement And general Release
This Confidential Severance Agreement and General Release (“Agreement”) is made by and between Xxxxxx Xxxxx, M.D., M.P.H. (“Employee”) and Xxxxx Therapeutics, Inc., a Delaware corporation (“Company”) (collectively, the “Parties”).
WHEREAS, Employee was employed by Company pursuant to that certain Employment Agreement dated April 30, 2024 and effective May 1, 2024 (the “Employment Agreement”);
WHEREAS, the Parties wish for the Employee to step down from his position as an officer and executive of the Company effective October 9, 2024 (“Step-Down Date”) and continue employment through a transition period until the Termination Date (as defined below);
WHEREAS, Employee’s employment shall terminate on December 13, 2024 or, if earlier, the date Employee ceases providing services to the Company (the “Termination Date”); and
WHEREAS, Employee and Company wish to set forth the terms of Employee’s separation from Company and to resolve any and all claims or disputes claims arising or in any way related to Employee’s employment with or separation from Company.
NOW THEREFORE, in consideration of the promises made herein, the Parties hereby agree as follows:
From the Step-Down Date to and including the Termination Date (the “Transition Period”), Employee agrees to cooperate fully with the Company and in good faith to provide all services that may be reasonably requested by the Company from time to time to ensure a smooth and orderly transition of Employee’s duties and responsibilities. From and after the Step-Down Date, Employee shall no longer be, nor hold out to be, an officer, executive, member, manager, representative, or agent of the Company or any of its affiliates, and shall no longer hold any title with the Company or any of its affiliates. During the Transition Period, Employee shall remain on payroll at Employee’s current base salary rate (as of the Step-Down Date), less all applicable deductions and withholdings, and be covered by the Company’s group medical and dental plans, subject to the provisions, requirements, conditions, and limitations of such plans, which may be amended from time to time. During the Transition Period, Employee shall continue to perform such job duties for the Company and to assist
in such transition-related duties as the Company may deem necessary and appropriate. For the avoidance of doubt, this is to confirm that for as long as Employee remains on the Company’s payroll (i.e., during the Transition Period), Employee shall continue to fully comply with, and be bound by, any and all policies and procedures in effect for the Company’s employees, including all requirements contained therein.
For the avoidance of doubt and notwithstanding anything in the Employment Agreement to the contrary, by Employee’s signature below, Employee acknowledges and agrees that (i) Employee’s termination is not a CIC Qualifying Termination, as such term is defined in the Employment Agreement, and (ii) except for the Separation Benefits, after the Termination Date, Employee will not be entitled to any other or further compensation, bonuses, fees, equity grants, remuneration, or benefits from Company.
a)the Agreement, which includes the ADEA Release, was negotiated at arms-length;
b) | the Agreement, which includes the ADEA Release, is worded in a manner that Employee fully understands; |
c)Employee specifically waives any rights or claims under the ADEA;
d) | Employee knowingly and voluntarily agrees to all of the terms set forth in the Agreement, which includes the ADEA Release; |
e) | Employee acknowledges and understands that any claims under the ADEA that may arise after the Termination Date are not waived; |
f) | the rights and claims waived in this Agreement, which includes the ADEA Release, are in exchange for consideration over and above anything to which Employee is already undisputedly entitled; |
g)Employee has the right to consult with an attorney before signing this Agreement;
h)Employee has twenty-one (21) days to consider whether to sign this Agreement; and
i) | Employee has seven (7) days after signing this Agreement to revoke his acceptance to this Agreement, and this Agreement will not be effective, and Employee will not receive any of the Separation Benefits described herein, until that revocation period has expired, which shall be the eighth (8th) day after Employee signs the Agreement, assuming it is not revoked (such date, the “Effective Date”). |
If Employee wishes to revoke Employee’s acceptance of this agreement, Employee must deliver written notice stating Employee’s intent to revoke by email to Xxxx Xxxxxx, CFO, on or before 5:00 p.m. Eastern on the seventh (7th) day after the date on which Employee signs this Agreement. If the Agreement is revoked, Employee will not be entitled to the Separation Benefits under this Agreement. Nothing in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. The Parties agree that changes to this Agreement, whether material or immaterial, do not restart the running of the twenty-one (21) day review period
[Signature page to follow.]
Exhibit 10.1
IN WITNESS WHEREOF, the Parties have executed this Confidential Severance Agreement and General Release on the respective dates set forth below.
Dated: __10/9/2024______________ /s/ Xxxx Xxxxx
XXXXX THERAPEUTICS, INC.
Xxxx Xxxxx, Ph.D.
Its: Chief Executive Officer
Dated: __10/8/2024______________By /s/ Xxxxxx Xxxxx
Xxxxxx Xxxxx, M.D., M.P.H.